Advertisement
Home »

The addition of cisplatin to standard-of-care radiation therapy does not appear to improve progression-free survival for patients with localized recurrent endometrial cancer.

Apr 30, 2024

ABOUT THE CONTRIBUTORS

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement